DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer

Active, not recruiting

Conditions: Prostate Adenocarcinoma

Interventions: Radiation: Proton Therapy
Radiation: IMRT

First Posted Date: 2011-05-11

Last Posted Date: 2024-06-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 303

Registration Number: NCT01352429

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

PD0332991/Paclitaxel in Advanced Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: PD0332991
Drug: Paclitaxel

First Posted Date: 2011-03-22

Last Posted Date: 2020-04-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 28

Registration Number: NCT01320592

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Carcinoma
Fallopian Tube Cancer
Primary Peritoneal Cancer

First Posted Date: 2011-03-10

Last Posted Date: 2020-04-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 18

Registration Number: NCT01312376

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Primary Peritoneal Cancer
Ovarian Cancer

Interventions: Biological: OC-L/Montanide ISA 51 VG
Biological: Prevnar
Biological: Ampligen

First Posted Date: 2011-03-10

Last Posted Date: 2021-11-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 3

Registration Number: NCT01312389

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

The Effects of Radiation in Reconstructed Breasts

Completed

Conditions: Breast Cancer

First Posted Date: 2011-02-10

Last Posted Date: 2020-04-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 12

Registration Number: NCT01292772

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Brivanib Metastatic Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Drug: Brivanib alaninate
Genetic: Polymerase chain reaction
Other: Iodine I 124 chimeric monoclonal antibody G250
Procedure: Positron emission tomography/computed tomography
Genetic: Protein expression analysis
Other: Immunohistochemistry

First Posted Date: 2010-12-03

Last Posted Date: 2021-04-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT01253668

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Effect of Donepezil on Smoking

Phase 2

Completed

Conditions: Smoking

Interventions: Drug: Placebo
Drug: Donepezil

First Posted Date: 2010-12-01

Last Posted Date: 2019-07-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT01250977

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

Early Phase 1

Completed

Conditions: Carcinoma, Renal Cell

First Posted Date: 2010-10-15

Last Posted Date: 2020-03-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT01221506

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study

Completed

Conditions: Malignancy
Glioma
Radiotherapy

Interventions: Radiation: Photon treatment plans
Radiation: Proton Treatment Plans
Behavioral: Neurocognitive evaluation
Device: Advanced MRI imaging

First Posted Date: 2010-10-01

Last Posted Date: 2020-04-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 60

Registration Number: NCT01212731

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Intrapleural Gene Transfer for Pleural Mesothelioma

Phase 1

Completed

Conditions: Malignant Pleural Mesothelioma

Interventions: Biological: SCH 721015

First Posted Date: 2010-09-30

Last Posted Date: 2015-09-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 13

Registration Number: NCT01212367

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy